A case of successful allogeneic bone marrow transplantation in a HBV-positive severe aplastic anemia patient with prophylactic lamivudine treatment.
- Author:
Yoon Kyoung SUNG
1
;
Myung Ju AHN
;
Ho Suk OH
;
Jung Hye CHOI
;
Young Yeol LEE
;
In Soon KIM
;
Il Young CHOI
Author Information
1. Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Korea. mjahn@hmc.hanyang.ac.kr
- Publication Type:Case Report
- Keywords:
Lamivudine;
HBV;
Allogeneic bone marrow transplantation
- MeSH:
Adult;
Anemia, Aplastic*;
Bone Marrow Transplantation*;
Bone Marrow*;
DNA;
Drug Therapy;
Female;
Hepatitis B;
Hepatitis B virus;
Hepatitis B, Chronic;
Humans;
Lamivudine*;
Liver Diseases
- From:Korean Journal of Medicine
2004;66(1):75-79
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Reactivation of hepatitis B virus (HBV) infection has been known to be a serious complication of immunosuppressive or cytotoxic chemotherapy in HBV carriers or chronic hepatitis B patients. We report here a 25-year-old woman who has severe aplastic anemia and chronic hepatitis B underwent successful allogeneic bone marrow transplantation (BMT) with prophylactic lamivudine treatment and showed no evidence of reactivation of hepatitis B, HBV DNA elevation, or liver dysfunction. This result suggests that prophylactic administration of lamivudine to a BMT recipient of chronic hepatitis B might be a safe and promising measure to prevent fatal liver dysfunction.
